31126. Misbranding of Sulpho-Lythin preparations.    U. S. v. 2 Bottles of Sulpho-
Lythin (and 5 other seizure actions involving Sulpho-Lythin prepara- 
tions). Default decrees of condemnation and destruction. (F. & D. Nos. 
442S8 to 44303, incl. Sample Nos. 13513-E to 13516-E. Incl., 2911U-D. 
29170-D.)
The labeling of these products bore false and fraudulent curative aad 
therapeutic claims and false and misleading representations regarding their 
composition.
On December 2, 1938, the United States attorney for the Northern District 
of Georgia filed libels against 31 bottles of Sulpho-Lythin (powder), 5 bottles 
of Sulpho-Lythin (liquid), 4 bottles of Sulpho-Lythin with Sdli.State of Stron- 
tium, and 5 bottles of Sulpho-Lythin with Hexamethylenamine, at Atlanta, Ga., 
alleging that the articles had been shipped in interstate commerce within the 
period from on or about May 7 to on or about October 12, 1938, by the Laine 
Chemical Corporation from Long Island City, N. Y.; and charging that they 
were misbranded in violation of the Food and Drugs Act as amended.
Analyses showed that the Sulpho-Lythin powder consisted essentially of 
sodium phosphate and sodium thiosulfate with relatively small proportions 
of sodium sulfate, sodium chloride, and a lithium compound; and that the 
Sulpho-Lythin liquid consisted essentially of sodium thiosulfate and water 
with relatively small proportions of sodium phosphate, sodium sulfate, sodium 
chloride, and a lithium compound.
Both products were alleged to be misbranded in that the designation "Sulpho- 
Lythin" was false and misleading as applied to an article of the composition 
of these products. They were alleged to be misbranded further in that the 
following statements appearing in the labeling regarding their curative or 
therapeutic effects were false and fraudulent: "Hepatic Stimulant Intestinal 
Antiseptic and Uric Acid Eliminant * * * Sulpho-Lythin is indicated in 
hepatic torpor, and all conditions arising from a functionally inactive or 
deranged liver such as Acid Toxemia, Auto Intoxication and Uric-Acid Excess. 
In correcting intestinal fermentation and eliminating toxins from the intestinal 
tract, it can be used instead of Calomel and is free from injurious action 
even if taken for extended periods. The continuous use of Sulpho-Lythin 
will keep the secretions of the mouth normally protective in uric acid 
conditions. * * * decidedly increases the action of the sluggish liver and 
kidneys. * * * There will be no bowel action following its administration 
until the liver responds." The Sulpho-Lythin liquid was alleged to.be mis- 
branded further in that it was an imitation of and was offered for sale under 
the name of another article, namely, "Sulpho-Lythin," since its composition 
was materially different from that of the product designated "Sulpho-Lythin."
Analysis showed that the Sulpho-Lythin with salicylate of strontium con- 
sisted essentially of strontium salicylate, sodium phosphate, sodium thiosulfate 
and relatively small proportions of sodium sulfate, sodium chloride, and a 
trace of a lithium compound. It was alleged to be misbranded in that the 
designation "Sulpho-Lythin with Salicylate of Strontium" was false and mis- 
leading as applied to a product of the composition of this article. It was 
alleged to be misbranded further in that the following statements in the 
labeling regarding its curative and therapeutic effects were false and fraudulent: 
"Acute or Chronic Rheumatic and Gouty Affections and conditions arising 
from Uric Acid Excess or Auto-toxemia. * * * Influenza, Grippe, Tonsillitis, 
Bronchial Catarrh and all
'Catarrhal affections that may be caused by or influ- 
enced by autointoxication. * * * In acute conditions two tablets may be 
given every hour (taken as a pill) until the symptoms subside, and the diet 
should be restricted. Then two to four tablets may- be given twice or three 
times a day and continued as long as required. In chronic conditions, two to 
four tablets may be given twice or three times a day, half an hour before 
meals."
Analysis showed that the Sulpho-Lythin with hexamethylenamine consisted 
essentially of hexamethylenamine, sodium phosphate, sodium thiosulfate, and 
relatively small proportions of sodium sulfate, sodium chloride, and a lithium 
compound. It was alleged to be misbranded in that the. statement "Sulpho- 
Lythin with Hexamethylenamine" was false and misleading as applied to a 
product of the composition of this article. It was alleged to be misbranded 
further in that the following statements regarding its curative or therapeutic 
effects, appearing in the labeling, were false and fraudulent: "Urinary and 
Biliary Antiseptic, Hepatic Stimulant and Intestinal Antiseptic. ?* * * 
(Biliary, Urinary and Intestinal Antiseptic.) Effective in arresting, preventing 
and counteracting bacterial invasion of the gall bladder. Hence it is indicated 
in Cholangitis, Cholecystitis and Cholelithiasis. Effective in the Acute or Chronic 
Inflammation of the Urinary tract, including Bladder and Kidneys. Effective 
in Typhoid Fever and in other conditions requiring an intestinal antiseptic."
On January 28, 1941, the Laine Chemical Corporation, claimant, having with- 
drawn its claim and answer, judgments of condemnation were entered and the 
products were ordered destroyed.